Translumbosacral Neuromodulation Shows Promise for Fecal Incontinence, suggests study
A randomized trial published in the journal of Gastroenterology found that translumbosacral neuromodulation therapy (TNT) was safe and significantly improved fecal incontinence and bowel symptoms compared with a sham treatment. The findings suggest this noninvasive therapy may offer an effective new option for managing bowel dysfunction.
Fecal incontinence (FI) affects millions of people globally and can severely impact quality of life, emotional well-being, and social functioning. The disorder is often caused by a combination of nerve damage, pelvic floor dysfunction, muscle weakness, and impaired rectal sensation. Existing treatments which includes dietary modification, medications, pelvic floor therapy, and surgery, often provide incomplete relief. This study evaluated whether TNT could improve bowel control by stimulating lumbosacral nerve pathways involved in anorectal function.
In this double-blind, randomized, sham-controlled trial, 109 patients experienced at least one fecal incontinence episode per week were assigned to receive either active TNT therapy or sham treatment. The participants in the active treatment groups received either 2,400 or 3,600 repetitive magnetic pulses delivered weekly over six weeks at four lumbosacral stimulation sites. The primary outcome measured was at least a 50% reduction in weekly fecal incontinence episodes.
Almost 66% of patients in the 2,400-pulse group achieved the primary response target, while the response rate rose to more than 81% in the 3,600-pulse group. By comparison, only 32% of patients receiving sham treatment experienced similar improvement. Both active treatment groups demonstrated significantly superior outcomes when compared to placebo, with the higher-dose stimulation producing the strongest effects.
TNT significantly improved scores on the Fecal Incontinence Severity Index (FISI) in addition to reducing incontinence episodes. Quality-of-life measures also improved in the treatment groups, particularly in areas related to emotional well-being, coping, and social functioning.
Physiological testing revealed improvements in anorectal nerve conduction and anal squeeze pressures among patients receiving active therapy. These findings suggest that TNT may directly enhance neuromuscular function rather than simply masking symptoms.
No serious treatment-related adverse events were reported during the study. Mild side effects included temporary back pain in a small number of patients, along with isolated reports of tingling sensations and urinary urgency.
These results are especially important because TNT is entirely non-invasive and does not require surgery or implanted devices. Existing neuromodulation therapies for fecal incontinence, such as sacral nerve stimulation, often involve invasive procedures and implanted hardware.
Overall, these findings support the growing role of neuromodulation in gastrointestinal disorders and highlight the importance of targeting underlying nerve dysfunction in fecal incontinence treatment.
Source:
Rao, S. S. C., Yan, Y., Hamdy, S., Staller, K., Fidel, K., Aziz, A., Sharma, A., Clukey, J., Ayyala, D., & Kuo, B. (2026). Randomized sham controlled trial of translumbosacral neuromodulation therapy for fecal incontinence. Gastroenterology. https://doi.org/10.1053/j.gastro.2026.04.027
